HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?
Hologic set to end sales of Fluoroscan InSight FD in 2025 but sees strong momentum from DXA systems and broader business growth.
Hologic's Strong International Traction to Continue Despite Headwinds
HOLX's global push shows strength, with surgical growth and rising diagnostics use offsetting near-term challenges.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
Two MedTech giants, one clear winner. Boston Scientific's momentum outpaces Hologic's cautious rise.
Here's Why Hologic (HOLX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
